Abstract: The present invention relates generally to modified microorganisms suitable for use as live in ovo vaccines for avian species. The live in ovo vaccines of the present invention are useful for inducing immunity before or immediately after hatching against a virulent form of the modified microorganism or a microorganism immunologically related to the modified microorganism or a virulent organism or virus carrying an antigenic determinant expressed by the modified microorganism in the live vaccine. The subject live in ovo vaccines are particularly efficacious in enhancing the survival rate of newly-hatched poultry birds.

Abstract: Nucleotide sequences obtained from the genome of the capsid gene of FCV strain 2280 wherein the splicing sites have been modified, so as to be deleted or inactivated are provided. The nucleotide sequences include DNA sequences that encode polypeptides, such as the capsid gene of FCV strain 2280, whereby the coding sequences are capable of being transcribed in the nucleus of a eukaryotic organism without the DNA coding sequence being altered by the organism's natural splicing machinery and the amino acid structure of the expressed protein is not altered. The recombinant molecules may be incorporated into FHV-1 vectors that are used to infect cell cultures for use, inter alia, in the development of vaccines and, in particular vaccines for preventing or treating FCV disease.

Abstract: This invention provides, low molecular weight, non-peptide inhibitors of matrix metalloproteinases and TNF-&agr; converting enzyme (TACE, tumor necrosis factor-&agr; converting enzyme) of formula: B wherein B is P and Q are provided that when P is Q is and vice versa; or a pharmaceutically acceptable salt thereof.

Abstract: Compounds of the formula: are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

Abstract: A protein from H. influenzae designated NucA is isolated and purified. The NucA protein has the amino acid sequence of amino acids 26-603 of SEQ ID NO.2 or a biologically equivalent amino acid sequence thereof. Amino acids 1-25 of SEQ ID NO.2 are the signal peptide, which is cleaved during processing of the mature protein. The NucA protein has a molecular weight of approximately 63,000 Daltons as measured on a 12% SDS-PAGE gel and possesses 5′-nucleotidase activity. The NucA protein is obtained by isolation and purification from the H. influenzae organism, by chemical synthesis or by recombinant expression by an isolated and purified nucA DNA sequence which encodes the NucA protein. Such a DNA sequence hybridizes under standard high stringency Southern hybridization conditions with a DNA sequence encoding the NucA protein of H. influenzae having the amino acid sequence of amino acids 26-603 of SEQ ID NO.2 or a biologically equivalent amino acid sequence thereof.

Abstract: An aqueous spray composition comprising about 0.0001 to 1 wt/wt % of a water-soluble poly(ethylene oxide) having a molecular weight greater than about 5×105 Daltons and at least about 0.05 wt/wt % of a surfactant selected from the group consisting of a sulfonate surfactant and a sulfate surfactant. Said compositions exhibit reduced spray drift. Said compositions are employed in methods for increasing the median diameter of spray droplets and have utility in agricultural spray applications.

Abstract: The present invention provides a method to control parasitic mites on beneficial insects, such as honeybees, via the application of a parasiticidally effective amount of tebufenpyrad.

Abstract: The invention is a method of treatment for the relief of an addictive, compulsive disorder which comprises the administration to a human or animal suffering from such a disorder an effective amount of the compound of the formula: wherein R is hydrogen, alkyl (C1-C6); R1 is hydrogen, mono or disubstituted halogen, alkoxy (C1-C3), CF3, alkyl (C1-C6); and R2 is hydrogen, methyl or ethyl, or a pharmaceutically acceptable salt thereof.

Abstract: Compounds of the formula: are useful in treating disease conditions mediated by TNF-&agr; such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

Abstract: The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g.

Abstract: A process is disclosed for the preparation of 5-bromo-2-fluorobenzeneboronic acid, which is useful as an intermediate in the preparation of a non-ester pyrethroid compound. The compound can be, for example, a fluoroolefin, which is useful as a pesticide.

Abstract: A system for delivery of fluid material, and more particularly, a bait station for delivery of fluid insecticide, is formed from a base having at least one feeding station, and a reservoir for storing fluid insecticides beneath the base. The insecticide is transferred by capillary action from the reservoir to the feeding station through at least one connecting tube. At least one hollow member extends upwardly from the base to support a cover removably mounted over the base, and to provide a conduit for refilling the reservoir with fluid. The cover and the base are designed to provide access to insects to the feed station when the cover is mounted over the base.

Abstract: Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-&agr; converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-&agr; from membrane bound TNF-&agr; precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states.

Abstract: A device for metering flowable material is formed from two components which are movable relative to each other. The relative movement of the components varies the width of a gap between the components to control the flow of material through the gap. One of the movable components carries a rotatable element to direct the flow of material towards the gap, and a guide element is provided to direct propelled material into the gap. The rotatable element is preferably a disk, and the gap is a channel located proximate to the periphery of the disk. An element mountable to and rotatable with the disk can be provided to act on and reduce the size of solid or semi-solid material carried by flowing fluid to permit such material to flow through the device.

Abstract: An improved process for the preparation of 6-(perfluoroalkyl)uracil compounds having the structural formula I from urea compounds having the structural formula II

Abstract: Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-&agr; converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-&agr; from membrane bound TNF-&agr; precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states. The present invention provides low molecular weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF-&agr; converting enzyme (TACE) for the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection.

Abstract: The present invention is directed to antibodies, in particular monoclonal antibodies, of porcine somatotropin (pST). When these antibodies are administered together with pST, the growth of vertebrates is greater than that achieved with the administration of pST alone. The invention is also directed to an increase in the growth of vertebrates which persists over long periods when an antibody to a somatotropin is administered together with such somatotropin.

Abstract: The invention relates to a process for the preparation of a 1,1,1-trifluoro-2-aminoalkane of formula I ##STR1## wherein R.sup.1 represents an optionally substituted alkyl group; which comprises heating a mixture consisting essentially of a compound of formula II ##STR2## wherein R.sup.1 has the meaning given, and R.sup.2 represents an optionally substituted aryl group, a primary amine, and optionally a base and/or an inert diluent, whereby the compound of formula I is removed by distillation during the heating procedure.

Abstract: The present invention relates to cyclodextrin derivatives, and methods for the preparation thereof, which cyclodextrin derivatives have at least one but no more than N-1 "higher" alkyl groups and at least one but no more than N-1 sulfate groups, wherein the total combined number of "higher" alkyl groups and sulfate groups does not exceed N, and further wherein N is the number of hydroxyl groups of the cyclodextrin from which the derivative was derived. The "higher" alkyl groups are lipids and, more particularly, aliphatic or aromatic carbon chains, especially linear carbon chains having a general structure of --O--C(.dbd.O)--(CH.sub.2).sub.n --CH.sub.3, wherein n is between 6 and 24 and/or --OC(.dbd.O)--(CH.sub.2).sub.m --CH.dbd.CH--(CH.sub.2).sub.m --CH.sub.3, wherein m is at least 6. The sulfate groups disclosed herein are sulfate groups having the formula --OSO.sub.3 R, wherein R may be H, Na, K, Li, NH.sub.4 and/or other atoms/molecules that form monovalent cations.

Abstract: The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha.